Protective porcine influenza virus-specific monoclonal antibodies recognize similar haemagglutinin epitopes as humans

Abstract
Pigs are natural hosts for the same subtypes of influenza A viruses as humans and integrally involved in virus evolution with frequent interspecies transmissions in both directions. The emergence of the 2009 pandemic H1N1 virus illustrates the importance of pigs in evolution of zoonotic strains. Here we generated pig influenza-specific monoclonal antibodies (mAbs) from H1N1pdm09 infected pigs. The mAbs recognized the same two major immunodominant haemagglutinin (HA) epitopes targeted by humans, one of which is not recognized by post-infection ferret antisera that are commonly used to monitor virus evolution. Neutralizing activity of the pig mAbs was comparable to that of potent human anti-HA mAbs. Further, prophylactic administration of a selected porcine mAb to pigs abolished lung viral load and greatly reduced lung pathology but did not eliminate nasal shedding of virus after H1N1pdm09 challenge. Hence mAbs from pigs, which target HA can significantly reduce disease severity. These results, together with the comparable sizes of pigs and humans, indicate that the pig is a valuable model for understanding how best to apply mAbs as therapy in humans and for monitoring antigenic drift of influenza viruses in humans, thereby providing information highly relevant to making influenza vaccine recommendations. Antibodies (Ab) are increasingly used to treat human infectious diseases. Pigs are large animals, natural hosts for influenza viruses and very similar to humans. We generated monoclonal Abs from influenza infected pigs and show that they recognize the same sites of the virus as humans. One of these sites was not recognized by ferret anti-sera, which are commonly used to predict the evolution of the virus and inform vaccine design. We also show that prophylactic administration of one of these mAb to pigs abolished lung viral load and prevented lung damage following infection with influenza. We conclude that the pig is a useful model to test how best to use Abs for therapy and to inform vaccine recommendations for humans.
Funding Information
  • Bill & Melinda Gates Foundation (OPP1201470)
  • Bill & Melinda Gates Foundation (OPP1201470)
  • Bill & Melinda Gates Foundation (OPP1201470)
  • Bill and Melinda Gates Foundation (OPP1201470)
  • Bill and Melinda Gates Foundation (OPP1201470)
  • Bill & Melinda Gates Foundation (OPP1215550)
  • Bill & Melinda Gates Foundation (OPP1215550)
  • Bill & Melinda Gates Foundation (OPP1215550)
  • Bill & Melinda Gates Foundation (OPP1215550)
  • Bill & Melinda Gates Foundation (OPP1215550)
  • Bill & Melinda Gates Foundation (OPP1215550)
  • Bill & Melinda Gates Foundation (OPP1215550)
  • Bill & Melinda Gates Foundation (OPP1215550)
  • Bill & Melinda Gates Foundation (OPP1215550)
  • Bill & Melinda Gates Foundation (OPP1215550)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007031)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007031)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007031)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007031)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007031)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007031)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007031)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007031)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007031)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007031)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007038)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007038)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007038)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007038)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007038)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007038)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007038)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007038)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007038)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007038)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007039)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007039)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007039)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007039)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007039)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007039)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007039)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007039)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007039)
  • Biotechnology and Biological Sciences Research Council (BBS/E/I/00007039)
  • CAMS (2018-I2M-2-002)
  • CAMS (2018-I2M-2-002)
  • Townsend-Jeantet Prize Charitable Trust (1011770)
  • Townsend-Jeantet Prize Charitable Trust (1011770)
  • Medical Research Council (MR/P021336/1)
  • Medical Research Council (MR/P021336/1)
  • MRC, BBSRC, EU and ESPRC
  • Francis Crick Institute/Cancer Research UK (FC001030)
  • Francis Crick Institute/Cancer Research UK (FC001030)
  • Medical Research Council (FC001030)
  • Medical Research Council (FC001030)
  • Wellcome Trust (FC001030)
  • Wellcome Trust (FC001030)